Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2019
Oct 15, 2019
7:00 AM EDT
The appointment of Thomas Schlumpberger , Ph.D., as Executive Vice President, Diagnostics. Dr. Schlumpberger will be responsible for the development and commercialization of Cchek™, Anixa's artificial intelligence driven liquid biopsy for early cancer detection.
Oct 10, 2019
7:00 AM EDT
The appointment of Ian H. Frazer , MD, AC, FRS, FAA, to its Scientific Advisory Board.
Sep 23, 2019
7:00 AM EDT
Mohummad Siddiqui , MD, Associate Professor of Surgery at the University of Maryland School of Medicine (UMSOM) has joined its ongoing prostate cancer Cchek™ study.
Sep 19, 2019
7:00 AM EDT
Potomac Urology Center, PC ("PUC") has joined its Cchek™ early cancer detection study. PUC will provide patient samples for Anixa's ongoing prostate cancer study, including support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test.
Sep 16, 2019
7:00 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on harnessing the body's immune system to fight cancer, congratulates H. Michael Shepard , Ph.D., a member of Anixa's Scientific Advisory Board, as a recipient of the 2019 Lasker-DeBakey Clinical Medical Research Award in recognition of his…
Aug 26, 2019
7:00 AM EDT
Its participation at two upcoming investor conferences in New York City .
Jul 29, 2019
7:00 AM EDT
The VA North Texas Health Care System and its non-profit affiliate, the Dallas VA Research Corporation, have joined Anixa's ongoing prostate cancer Cchek™ study. Study enrollment will be led by Dr. Manoj Reddy , Radiation Oncologist, and Dr. Jeffrey Gahan , Chief of Robotic Surgery.
Jul 24, 2019
7:00 AM EDT
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,360,499, a key component of Anixa's Cchek™ technology for early detection of cancer.
Jul 22, 2019
7:00 AM EDT
It is partnering with the VA Maryland Health Care System's Baltimore VA Medical Center and the Baltimore Research and Education Foundation, a non-profit affiliate, in its ongoing prostate cancer Cchek™ study. Led by Dr.
Jul 17, 2019
7:00 AM EDT
It has established a strategic alliance and license agreement with Cleveland Clinic for an innovative breast cancer vaccine technology.
Jul 16, 2019
7:00 AM EDT
It will make available reprints of a recent study in the Journal of Experimental Medicine (JEM) entitled, "Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs" jointly published with collaborators at The Wistar Institute.
May 29, 2019
7:00 AM EDT
It will present updated data from its study utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology, at CYTO 2019 – 34 th Congress of the International Society for Advancement of Cytometry (ISAC) in Vancouver, BC , Canada.
May 21, 2019
7:00 AM EDT
It will be presenting at the Sachs Associates 5 th Annual Immuno-Oncology BD&L and Investment Forum to be held May 31, 2019 in Chicago.
May 13, 2019
7:00 AM EDT
Its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test successfully passed all required initial analytical verification studies en route to commercialization and implementation in the ResearchDx facility.
May 02, 2019
7:00 AM EDT
It will be presenting at the 20 th Annual B. Riley FBR Institutional Investor Conference to be held May 22–23, 2019, at the Beverly Hilton Hotel in Beverly Hills , CA. Dr. Amit Kumar , Chairman, President and CEO of Anixa, will be presenting, as well as meeting with investors.
Apr 11, 2019
7:00 AM EDT
It has extended and expanded its collaboration with New Jersey Urology, LLC ("NJU"). Pursuant to the extension, NJU will continue to provide patient samples for Anixa's ongoing Cchek™ early cancer detection study.
Apr 03, 2019
2:00 PM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study on prostate cancer detection, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the 2019 annual meeting of…
Mar 27, 2019
7:00 AM EDT
Dr. Amit Kumar , CEO of Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, will participate in a panel presentation discussing the latest science in immunotherapy at a two day symposium titled, " Frontiers in Cancer Immunotherapy , " hosted by…
Mar 14, 2019
7:00 AM EDT
The United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for an additional cancer detection technology patent. This patent provides broader coverage for the use of Anixa's technology in a wider range of applications and protects critical new improvements developed for Anixa's cancer…
Mar 04, 2019
7:00 AM EST
It will present its Cchek™ artificial intelligence (AI) based liquid biopsy for the early detection of cancer technology and its most recent data in an oral presentation at the 26 th International Molecular Medicine Tri-Conference.
